Parsemus Foundation: Difference between revisions
update link |
add ref |
||
| Line 3: | Line 3: | ||
==Background== |
==Background== |
||
Parsemus is an advocate of research into the plausibility of [[Reversible inhibition of sperm under guidance|RISUG]], a reversible [[male contraceptive]].<ref name='Haine 2010-07-05'> {{cite news | first = Rosie | last = Haine | title = Men need more contraceptive choice | date = 2010-07-05 | url = http://www.bbc.co.uk/news/10514490 | work = BBC News | accessdate = 2012-10-13}}</ref> The foundation began procuring RISUG's United States [[intellectual property]] rights in November 2010, completed the acquisition process in February 2012, and is now conducting [[toxicology testing|toxicology tests]] as an initial step towards [[Food and Drug Administration]] approval.<ref name='Beck 2011-06-14'> {{cite news | first = Melinda | last = Beck | title = 'Honey, It's Your Turn...' | date = 2011-06-14 | url = https://online.wsj.com/article/SB10001424052702303848104576383730320049892.html | work = The Wall Street Journal | accessdate = 2012-10-13}}</ref><ref> {{cite web | url = http://parsemusfoundation.org/Parsemus/New_male_contraceptives.html | title = Parsemus Foundation | accessdate = 2012-10-13}}</ref> Animal trials have thus far proved effective with no negative side effects; human trials are being planned for 2015-2016 with a possible market release by 2017.<ref>http://www.parsemusfoundation.org/vasalgel-faqs/</ref> |
Parsemus is an advocate of research into the plausibility of [[Reversible inhibition of sperm under guidance|RISUG]], a reversible [[male contraceptive]].<ref name='Haine 2010-07-05'> {{cite news | first = Rosie | last = Haine | title = Men need more contraceptive choice | date = 2010-07-05 | url = http://www.bbc.co.uk/news/10514490 | work = BBC News | accessdate = 2012-10-13}}</ref> The foundation began procuring RISUG's United States [[intellectual property]] rights in November 2010, completed the acquisition process in February 2012, and is now conducting [[toxicology testing|toxicology tests]] as an initial step towards [[Food and Drug Administration]] approval.<ref name='Beck 2011-06-14'> {{cite news | first = Melinda | last = Beck | title = 'Honey, It's Your Turn...' | date = 2011-06-14 | url = https://online.wsj.com/article/SB10001424052702303848104576383730320049892.html | work = The Wall Street Journal | accessdate = 2012-10-13}}</ref><ref> {{cite web | url = http://parsemusfoundation.org/Parsemus/New_male_contraceptives.html | title = Parsemus Foundation | accessdate = 2012-10-13}}</ref><ref name="Priceonomics">{{cite news |url=https://priceonomics.com/the-economics-of-male-birth-control/ |title=The Economics of Male Birth Control |work=Priceonomics |date=2015-10-19 |accessdate=2017-03-21 }}</ref> Animal trials have thus far proved effective with no negative side effects; human trials are being planned for 2015-2016 with a possible market release by 2017.<ref>http://www.parsemusfoundation.org/vasalgel-faqs/</ref> |
||
The foundation was also noted for its support of the ''[[Archives of Internal Medicine]]'''s ''less-is-more'' series.<ref name='ORiordanin 2011-07-15'/><ref name='Brownlee 2011-07-19'> {{cite news | first = Shannon | last = Brownlee | title = Less Is More | date = 2011-07-19 | url = http://health.newamerica.net/blogposts/2011/less_is_more-55062 | work = New America Foundation | accessdate = 2012-10-13}}</ref> |
The foundation was also noted for its support of the ''[[Archives of Internal Medicine]]'''s ''less-is-more'' series.<ref name='ORiordanin 2011-07-15'/><ref name='Brownlee 2011-07-19'> {{cite news | first = Shannon | last = Brownlee | title = Less Is More | date = 2011-07-19 | url = http://health.newamerica.net/blogposts/2011/less_is_more-55062 | work = New America Foundation | accessdate = 2012-10-13}}</ref> |
||
Revision as of 01:08, 21 March 2017
 | The topic of this article may not meet Wikipedia's general notability guideline. (April 2013) |
The Parsemus Foundation is an American non-governmental organization whose stated objective is to advance low cost evidence-based medicines not pursued by the pharmaceutical industry.[1] The foundation’s focus is on supporting small proof-of-concept studies and then pursuing press coverage of the results, so that the advances change treatment practice rather than disappearing into the scientific literature. Many of the studies supported involve low-cost approaches that are not under patent.
Background
Parsemus is an advocate of research into the plausibility of RISUG, a reversible male contraceptive.[2] The foundation began procuring RISUG's United States intellectual property rights in November 2010, completed the acquisition process in February 2012, and is now conducting toxicology tests as an initial step towards Food and Drug Administration approval.[3][4][5] Animal trials have thus far proved effective with no negative side effects; human trials are being planned for 2015-2016 with a possible market release by 2017.[6]
The foundation was also noted for its support of the Archives of Internal Medicine's less-is-more series.[1][7]
References
- ^ a b O'Riordan, Michael (2011-07-15). "What Is the Parsemus Foundation?". Heartwire. Medscape. Retrieved 2017-03-21.
- ^ Haine, Rosie (2010-07-05). "Men need more contraceptive choice". BBC News. Retrieved 2012-10-13.
- ^ Beck, Melinda (2011-06-14). "'Honey, It's Your Turn...'". The Wall Street Journal. Retrieved 2012-10-13.
- ^ "Parsemus Foundation". Retrieved 2012-10-13.
- ^ "The Economics of Male Birth Control". Priceonomics. 2015-10-19. Retrieved 2017-03-21.
- ^ http://www.parsemusfoundation.org/vasalgel-faqs/
- ^ Brownlee, Shannon (2011-07-19). "Less Is More". New America Foundation. Retrieved 2012-10-13.
External links
 | This article related to a non-profit organization is a stub. You can help Wikipedia by expanding it. |